{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:17:42Z","timestamp":1755217062161,"version":"3.43.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We conducted a phase I study to evaluate the recommended dose of S-1 in combination with cisplatin (SP) and concurrent carbon ion radiotherapy (CIRT) in patients with stage III locally advanced non-small cell lung cancer (LA-NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>S-1 was administered orally twice daily after a meal for 14 consecutive days, and cisplatin was administered on days 1 and 8. The dose of each drug in this study was planned as follows: level 0, S-1\u201330 mg\/m<jats:sup>2<\/jats:sup> twice daily and cisplatin 40 mg\/m<jats:sup>2<\/jats:sup>; level 1, S-1\u201340 mg\/m<jats:sup>2<\/jats:sup> twice daily and cisplatin 40 mg\/m<jats:sup>2<\/jats:sup>. CIRT was conducted at a total dose of 64 Gy (relative biological effectiveness) in 16 fractions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six patients were enrolled in this study. At level 1, one patient experienced grade 3 elevated alanine aminotransferase and aspartate aminotransferase levels, which is regarded as a dose-limiting toxicity. This event improved immediately. Five patients developed grade 2 esophagitis. In three of the five patients, symptoms such as pain and dysphagia due to esophagitis recurred several months after resolution of the acute esophagitis that occurred during irradiation. None of the patients experienced adverse events of \u2265grade 3. Thus, level 1 was determined to be the recommended dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Chemotherapy with SP and concurrent CIRT is feasible and well-tolerated in patients with Stage III LA-NSCLC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1573462","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:43Z","timestamp":1754371483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase I study of S-1 and cisplatin with concurrent hypofractionated carbon-ion radiotherapy for patients with stage III non-small cell lung cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Yosuke","family":"Miura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuteru","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Tsurumaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemasa","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.6.1710","article-title":"Revisions in the international system for staging lung cancer","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrw041","article-title":"Dosimetric comparison of carbon ion and X-ray radiotherapy for stage IIIA non-small cell lung cancer","volume":"57","author":"Kubo","year":"2016","journal-title":"J Radiat Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(98)00544-6","article-title":"Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy","volume":"44","author":"Kanai","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12298","article-title":"A Phase I Study of hypofractionated carbon-ion radiotherapy for stage III non-small cell lung cancer","volume":"38","author":"Saitoh","year":"2018","journal-title":"Anticancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29195","article-title":"A prospective nonrandomized phase I\/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC)","volume":"121","author":"Takahashi","year":"2015","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13963","article-title":"Safety and efficacy of carbon-ion radiotherapy alone for stage III non-small cell lung cancer","volume":"40","author":"Anzai","year":"2020","journal-title":"Anticancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rru085","article-title":"Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460","volume":"56","author":"Kubo","year":"2015","journal-title":"J Radiat Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-260","article-title":"Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro","volume":"8","author":"Schlaich","year":"2013","journal-title":"Radiat Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.lungcan.2020.01.008","article-title":"Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study","volume":"141","author":"Niho","year":"2020","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0243-2","article-title":"A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L","volume":"119","author":"Sasaki","year":"2018","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.11.001","article-title":"A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501","volume":"87","author":"Nogami","year":"2015","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.09.004","article-title":"Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer","volume":"82","author":"Kaira","year":"2013","journal-title":"Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.7577","article-title":"Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007","volume":"28","author":"Segawa","year":"2010","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1278-3218(00)80010-4","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non small-cell lung cancer","volume":"4","author":"Renard","year":"2000","journal-title":"Cancer Radiother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03885-4","article-title":"Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients","volume":"84","author":"Hosoya","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.05.035","article-title":"Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrab116","article-title":"Radiotherapy patterns of care for locally-advanced non-small cell lung cancer in the pre- and post-durvalumab era: A region-wide survey in a Japanese prefecture","volume":"63","author":"Kubo","year":"2022","journal-title":"J Radiat Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON)","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(02)03807-5","article-title":"Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer","volume":"55","author":"Tsujino","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1573462\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:43Z","timestamp":1754371483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1573462\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1573462"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1573462","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"article-number":"1573462"}}